Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?
NCT ID: NCT00867971
Last Updated: 2009-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2009-02-28
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ocular Hypertension Treatment Study (OHTS)
NCT00000125
Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma
NCT02891317
Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide
NCT01274039
The Effect of Labor on Intraocular Pressure Fluctuation in Healthy Eyes
NCT06016712
Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma
NCT01645319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RGH treated
Measuring intraoccular pressure
Measurement of intraoccular pressure by tonometry
Starting treatment with RGH
Measuring intraoccular pressure
Measurement of intraoccular pressure by tonometry
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measuring intraoccular pressure
Measurement of intraoccular pressure by tonometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treatment with recombinant growth hormone
Exclusion Criteria
* Family history of eye diseases
* elevated occular pressure prior to starting treatment
6 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Assaf Harofeh Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assaf harofeh medical center
Ẕerifin, , Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Youngster I, Rachmiel R, Pinhas-Hamiel O, Bistritzer T, Zuckerman-Levin N, de Vries L, Naugolny L, Eyal O, Braunstein R, Rachmiel M. Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressure. J Pediatr. 2012 Dec;161(6):1116-9. doi: 10.1016/j.jpeds.2012.05.024. Epub 2012 Jun 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
162/08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.